Tools Content :

 

Our websites

 
 

Oncology

Sanofi’s mission is to create solutions for currently unmet medical needs. Sanofi employ innovative approaches to attack cancer on all fronts and provide medicines adapted to the diverse profiles of patients.
 

Through its acquisitions and targeted partnerships, Sanofi is carrying out research on newly discovered aspects of cancer development, growth and progression.
Sanofi is a key actor in the field of oncology, particularly in chemotherapy, with three major products: Taxotere® (docetaxel), Eloxatin® (oxaliplatin) and Jevtana® (cabazitaxel).

  • The taxoid Taxotere® is a cornerstone of treatment for several types of cancer and is available in more than 100 countries.
  • The platinum-based agent Eloxatine® is a major treatment in colorectal cancer and is available in more than 70 countries.
  • Jevtana® is a new taxane derivative resulting from 14 years of research and development.

The oncology R&D portfolio comprises a large range of new anticancer treatments with different mechanisms of action. These include in particular cytotoxic, antimitotic, and antiangiogenic agents, as well as targeted therapies and monoclonal antibodies.

To help patients and their loved-ones understand and manage the disease, Sanofi collaborates with numerous patient support associations worldwide through its affiliates.

  

For more information, please consult the Summaries of Product Characteristics for the products available in your country.
 
Top of page

Further information

Partners

 

Research and Development

 

Tools menu:

© Sanofi 2004-2012 - All rights reserved - Update: September 09, 2011

Site complies with W3C WCAG 2.0 (new window, in english)